Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Retinoic acid regulation of one member of the human class I alcohol dehydrogenase (ADH) gene family was demonstrated, suggesting that the retinol dehydrogenase function of ADH may play a regulatory role in the biosynthetic pathway for retinoic acid. Promoter activity of human
ADH3
, but not ADH1 or ADH2, was shown to be activated by retinoic acid in transient transfection assays of Hep3B human
hepatoma
cells. Deletion mapping experiments identified a region in the
ADH3
promoter located between -328 and -272 bp which confers retinoic acid activation. This region was also demonstrated to confer retinoic acid responsiveness on the ADH1 and ADH2 genes in heterologous promoter fusions. Within a 34-bp stretch, the
ADH3
retinoic acid response element (RARE) contains two TGACC motifs and one TGAAC motif, both of which exist in RAREs controlling other genes. A block mutation of the TGACC sequence located at -289 to -285 bp eliminated the retinoic acid response. As assayed by gel shift DNA binding studies, the RARE region (-328 to -272 bp) of
ADH3
bound the human retinoic acid receptor beta (RAR beta) and was competed for by DNA containing a RARE present in the gene encoding RAR beta. Since ADH catalyzes the conversion of retinol to retinal, which can be further converted to retinoic acid by aldehyde dehydrogenase, these results suggest that retinoic acid activation of
ADH3
constitutes a positive feedback loop regulating retinoic acid synthesis.
...
PMID:Retinoic acid response element in the human alcohol dehydrogenase gene ADH3: implications for regulation of retinoic acid synthesis. 199 13
The transcription factor CCAAT/enhancer-binding protein (C/EBP) was found to selectively trans-activate one member of the human class I alcohol dehydrogenase (ADH) gene family. A comparison of the promoters for the three human class I ADH genes ADH1, ADH2, and
ADH3
indicated a very similar pattern of binding sites (sites A-F) for rat liver nuclear proteins located between -10 and -210 base pairs (bp). In all three promoters site A consisted of two binding sites for the transcription factor C/EBP closely flanking both sides of the TATA box, but C/EBP bound with much greater affinity to site A of ADH2. C/EBP also bound at two locations which coincide with site D (-120 bp) and site E (-160 bp) of all three promoters. Cotransfection studies of human
hepatoma
cells using ADH-cat fusions and a C/EBP expression plasmid indicated that the human ADH2 promoter responded well to C/EBP trans-activation whereas the human ADH1 and
ADH3
promoters, which bind C/EBP weakly, responded poorly. Individual mutations in several ADH2 nuclear factor-binding sites allowed the identification of four functional C/EBP-binding sites, i.e. two in site A as well as one each in sites D and E. Also, the ADH2 TATA box was found to be dispensable for C/EBP induction. Compared to ADH2 and
ADH3
, site A in ADH1 contains four extra base pairs between the two C/EBP motifs, and deletion of these nucleotides increased the C/EBP responsiveness of ADH1 presumably by changing the spacing of the two C/EBP motifs. Thus, sequence divergence of human class I ADH gene family members has led to forms which vary in their responsiveness to C/EBP. We suggest that C/EBP contributes to liver-specific expression of the human class I ADH gene family by selectively inducing the ADH2 gene via a TATA-independent mechanism during liver development.
...
PMID:The role of CCAAT/enhancer-binding protein in the differential transcriptional regulation of a family of human liver alcohol dehydrogenase genes. 205 Jun 67
The human ADH1, ADH2, and
ADH3
genes are closely related members of a gene family which are differentially expressed during liver development. To begin examining the mechanism of this tissue-specific and stage-specific expression, the 5'-flanking nucleotide (nt) sequences of the three genes were determined and the transcription start point (tsp) were identified. Sequences of all three genes indicated a high degree of homology (greater than 80% nt sequence identity) from the AUG translation start codon to about nt -780 relative to the tsp. Transient transfection assays of a set of plasmids containing various lengths of ADH 5'-flanking DNA fused to cat were performed in the HepG2 and Hep3B human
hepatoma
cell lines. The results indicated that the ADH2 promoter-proximal region was transcriptionally active in the absence of upstream sequences. To identify potential cis-acting elements in the ADH2 promoter-proximal region, a DNase I footprinting assay using a rat liver nuclear extract was used. Protection occurred in several locations including one, between nt -51 and -10, which shares homology with known binding sites for a previously identified rat-liver transcription factor called CCAAT/enhancer binding protein (C/EBP). Purified C/EBP was shown by footprint analysis to bind at two distinct sites in the ADH2 promoter located at nt -51 to -31 and -21 to -10. The TATA-box promoter element at nt -30 to -22 was not protected by C/EBP, but was partially protected by a factor in the rat liver nuclear extract. Thus, it is possible that the flanking C/EBP molecules may create a novel binding pocket for TFIID, the TATA-binding general transcription factor for RNA polymerase II. Alternatively, the C/EBP molecules may block access to the TATA box, and stimulate transcription of ADH2 by interacting with some component(s) other than TFIID.
...
PMID:Promoters for the human alcohol dehydrogenase genes ADH1, ADH2, and ADH3: interaction of CCAAT/enhancer-binding protein with elements flanking the ADH2 TATA box. 216 44
Three human alcohol dehydrogenase genes, ADH1, ADH2, and
ADH3
, were formed by tandem duplications and have diverged in their tissue-specific and developmental expression. Their proximal promoters remain 80-84% identical in sequence, approximately the same degree of identity as at synonymous sites in the coding regions of these three genes. To understand the evolution of tissue specificity, gene expression must be studied in many different cells and tissues. A systematic comparison of their promoters reveals the effects of subtle sequence differences on the binding of nuclear proteins to their cis-acting elements. There are differences in the affinity with which some proteins are bound to altered sites including C/EBP sites, USF/MLTF sites, and the G3T site (which binds Sp1). There are also differences in the sites that are occupied, e.g. CTF/NFI-related sites. These sequence differences are reflected in differences in gene expression in three cell lines. In H4IIE-C3
hepatoma
cells, the ADH1 promoter was more active than the ADH2 promoter, and the
ADH3
promoter was nearly nonfunctional. In HeLa cells, both ADH1 and ADH2 promoters directed expression; again the
ADH3
promoter was extremely weak. None of the three promoters had much activity in CV-1 cells. Coexpression of C/EBP alpha greatly stimulated expression of the ADH1 promoter in HeLa cells and in CV-1 cells, but only weakly stimulated expression in H4IIE-C3 cells. The stimulation of the ADH1 promoter by C/EBP alpha was comparable to that of ADH2, despite the weaker binding to the C/EBP sites that flank the TATA box in ADH1. The
ADH3
promoter was not greatly stimulated by C/EBP alpha, despite good binding of C/EBP alpha. These results demonstrate that small differences in the cis-acting elements affect affinity of binding by transcription factors and the pattern of gene expression.
...
PMID:Gene expression in a young multigene family: tissue-specific differences in the expression of the human alcohol dehydrogenase genes ADH1, ADH2, and ADH3. 863 48